Figure 4 | Scientific Reports

Figure 4

From: Peptide-mediated delivery of donor mitochondria improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation

Figure 4

Seahorse X-24 analysis of oxygen consumption rate (OCR). (A) OCR measured after 4 days of treatment under normal conditions; after injection of oligomycin (1 μM); after injection of uncoupler FCCP (0.5 μM); after injection of electron transport inhibitor rotenone (2 μM) (n  =  5). (B) Basal respiration (Basal), ATP-linked and maximal respiratory capacity (Max) quantified by normalization of OCR to total protein OD value. All data were deducted from the non-respiration background for each group (OCR level post-rotenone treatment). Cell respiration measured in control cybrid cells (Con), MELAS cybrid cells (MELAS); MELAS cybrid cells treated with Pep-1 alone (Pep-1), naked mitochondria (Mito), Pep-1-labeled mitochondria (Pep-1-Mito) or Pep-1-labeled mitochondria carrying the mtDNA3243 mutation (Pep-1-Mito3423). *p < 0.05, compared to control group; + p < 0.05, compared to MELAS group; # p < 0.05, compared to Pep-1 group; & p < 0.05, compared to Pep-1-Mito group.

Back to article page